Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in <i>CCNE1</i>-amplified ovarian cancer models

Victoria E. Brown, Yoon Jong Choi, Nealia C. House et al.|Cancer Research|2022

Cited by 13